Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In intraperitoneal, subcutaneous, and orthotopic injection models, MUC20 knockdown decreased tumour growth in immunodeficient mice.
|
29993037 |
2018 |
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
MUC20 knockdown with siRNA decreased cell viability, as well as migration and invasion induced by PSCs in HPAC and HPAF-II cells.
|
29993037 |
2018 |
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
MUC20 expression was assessed in tissue microarray and tumor specimens of EOC patients by immunohistochemistry.
|
26616226 |
2016 |
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
IHC was conducted to examine the expression of selected target markers MUC4, MUC13, and MUC20 in 186 ESCC resection samples and the relationships between their expression and tumor regression grade was analyzed.
|
26673820 |
2016 |
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
MUC20 overexpression significantly enhanced EOC cell migration and invasion, but not viability.
|
26616226 |
2016 |
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Moreover, MUC20 overexpression enhanced EGF-mediated migration and invasion, suggesting a critical role of EGFR in MUC20-mediated effects.
|
23262208 |
2013 |
Malignant neoplasm of endometrium
|
0.020 |
Biomarker
|
disease |
BEFREE |
This study was performed to explore the effect of MUC20 in endometrial cancer (EC).
|
30784116 |
2019 |
Endometrial Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
This study was performed to explore the effect of MUC20 in endometrial cancer (EC).
|
30784116 |
2019 |
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
High expression of MUC20 drives tumorigenesis and predicts poor survival in endometrial cancer.
|
30784116 |
2019 |
Squamous cell carcinoma of esophagus
|
0.020 |
Biomarker
|
disease |
BEFREE |
IHC was conducted to examine the expression of selected target markers MUC4, MUC13, and MUC20 in 186 ESCC resection samples and the relationships between their expression and tumor regression grade was analyzed.
|
26673820 |
2016 |
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Mucin (MUC) 20 has recently been implicated to play a role in human carcinogenesis.
|
26616226 |
2016 |
Squamous cell carcinoma of esophagus
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The expression of MUC13 and MUC20 in ESCC mainly occurred in the cytoplasm.
|
26323930 |
2015 |
Malignant neoplasm of endometrium
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
High levels of MUC20 expression in EC tumors were correlated with an unfavorable histologic subtype.
|
23262208 |
2013 |
Endometrial Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
High levels of MUC20 expression in EC tumors were correlated with an unfavorable histologic subtype.
|
23262208 |
2013 |
IGA Glomerulonephritis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The frequencies of the alleles and genotypes of MUC20 VNTR polymorphisms did not differ between patients with IgAN and healthy controls.
|
16508246 |
2006 |
IGA Glomerulonephritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
These characteristics suggest that the production of MUC20 is correlated with development and progression of IgAN and other renal injuries.
|
14565953 |
2004 |
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MUC20 high expression was associated with age, histology, positive peritoneal cytology, advanced stage, and lymph node metastasis (P < 0.05).
|
30784116 |
2019 |
Immunologic Deficiency Syndromes
|
0.010 |
Biomarker
|
group |
BEFREE |
In intraperitoneal, subcutaneous, and orthotopic injection models, MUC20 knockdown decreased tumour growth in immunodeficient mice.
|
29993037 |
2018 |
Pancreatic Ductal Adenocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway.
|
29993037 |
2018 |
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, immunohistochemical staining demonstrated that high MUC20 expression correlated with poor progression-free survival and high local recurrence rate of PDAC patients (n = 61).
|
29993037 |
2018 |
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Our results suggest that MUC20 enhances aggressive behaviors of EOC cells by activating integrin β1 signaling and provide novel insights into the role of MUC20 in ovarian cancer metastasis.
|
26616226 |
2016 |
Malignant neoplasm of pancreas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Analysis using the Gene Expression Omnibus public microarray database indicated higher DUSP28, MUC1, MUC4, MUC5B, MUC16 and MUC20 messenger RNA (mRNA) levels in pancreatic cancers compared with normal pancreas tissues.
|
27230679 |
2016 |
Epithelial ovarian cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MUC20 overexpression significantly enhanced EOC cell migration and invasion, but not viability.
|
26616226 |
2016 |
Carcinoma, Ovarian Epithelial
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MUC20 overexpression significantly enhanced EOC cell migration and invasion, but not viability.
|
26616226 |
2016 |
Ulcerative Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Differential Expression of MUC12, MUC16, and MUC20 in Patients with Active and Remission Ulcerative Colitis.
|
26770020 |
2015 |